A Phase 1, Open-label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Patients With Unresectable, Recurrent, Locally-advanced, or Metastatic Solid Tumors

Trial Profile

A Phase 1, Open-label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Patients With Unresectable, Recurrent, Locally-advanced, or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs UCB 6352 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2017 According to a Syndax Pharmaceuticals media release, company expects to present data at a scientific congress in the fourth quarter of 2017.
    • 10 Nov 2016 Status changed from planning to recruiting, according to a Syndax Pharmaceuticals media release.
    • 09 Aug 2016 According to a Syndax Pharmaceuticals media release, the company anticipates to initiate dosing in this trial later in the year 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top